These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 25453730

  • 1. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P.
    Clin Ther; 2014 Dec 01; 36(12):2072-2079. PubMed ID: 25453730
    [Abstract] [Full Text] [Related]

  • 2. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M, Narukawa M.
    Ann Pharmacother; 2017 Jul 01; 51(7):570-576. PubMed ID: 28622738
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ.
    Postgrad Med; 2013 May 01; 125(3):7-20. PubMed ID: 23748503
    [Abstract] [Full Text] [Related]

  • 4. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
    Monami M, Dicembrini I, Mannucci E.
    Nutr Metab Cardiovasc Dis; 2014 Jul 01; 24(7):689-97. PubMed ID: 24793580
    [Abstract] [Full Text] [Related]

  • 5. An update on the 'gliptins'.
    Drug Ther Bull; 2016 Dec 01; 54(12):138-141. PubMed ID: 27979881
    [Abstract] [Full Text] [Related]

  • 6. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G, Cahn A, Raz I.
    Diabetes Care; 2016 Aug 01; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract] [Full Text] [Related]

  • 7. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 01; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 8. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F.
    Nutr Metab Cardiovasc Dis; 2016 May 01; 26(5):380-6. PubMed ID: 27067162
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Baksh SN, McAdams-DeMarco M, Segal JB, Alexander GC.
    Pharmacoepidemiol Drug Saf; 2018 Jun 01; 27(6):660-667. PubMed ID: 29655237
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
    Mannucci E, Nreu B, Montereggi C, Ragghianti B, Gallo M, Giaccari A, Monami M, SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes.
    Nutr Metab Cardiovasc Dis; 2021 Sep 22; 31(10):2745-2755. PubMed ID: 34364771
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E, Monami M.
    Adv Ther; 2017 Jan 22; 34(1):1-40. PubMed ID: 27844335
    [Abstract] [Full Text] [Related]

  • 12. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
    Hirshberg B, Katz A.
    Curr Diab Rep; 2015 Nov 22; 15(11):87. PubMed ID: 26370698
    [Abstract] [Full Text] [Related]

  • 13. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
    Chang CH, Chang YC, Lin JW, Caffrey JL, Wu LC, Lai MS, Chuang LM.
    Int J Cardiol; 2016 Oct 01; 220():14-20. PubMed ID: 27389437
    [Abstract] [Full Text] [Related]

  • 14. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
    Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, SAVOR-TIMI 53 Steering Committee and Investigators*.
    Circulation; 2014 Oct 28; 130(18):1579-88. PubMed ID: 25189213
    [Abstract] [Full Text] [Related]

  • 15. Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Ramirez G, Morrison AD, Bittle PA.
    Endocr Pract; 2013 Oct 28; 19(6):1025-34. PubMed ID: 23757605
    [Abstract] [Full Text] [Related]

  • 16. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators.
    N Engl J Med; 2013 Oct 03; 369(14):1317-26. PubMed ID: 23992601
    [Abstract] [Full Text] [Related]

  • 17. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
    Špinar J, Špinarová L, Vítovec J.
    Vnitr Lek; 2015 Nov 03; 61(11):976-83. PubMed ID: 26652787
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
    Sharma A, Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Zannad F.
    J Am Heart Assoc; 2018 May 16; 7(11):. PubMed ID: 29769203
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.